Comparison Between Dexmedetomidine and Propofol for Patients in the Intensive Care Unit After Abdominal Surgery
Status:
Completed
Trial end date:
2018-07-20
Target enrollment:
Participant gender:
Summary
This is a single-blind randomized clinical trial. Patients undergoing abdominal surgery will
be enrolled and randomly divided into two groups: dexmedetomidine group and propofol group.
In the dexmedetomidine group, patients will receive continuous intravenous infusion of
dexmedetomidine (infusion dosage range: 0.1 ~ 0.7 mcg/kg/h). In the propofol group, patients
will receive continuous intravenous infusion of propofol (infusion dosage range: 0.3 ~ 1.6
mg/kg/h). Hemodynamics will be continuously monitored using a non-invasive monitoring with
chest bioreactance technique at preset time points (0, 2, 4, 6, 12h and 24h). Clinical data
such as vital signs, hemodynamic parameters, laboratory results and fluid balance will be
recorded. The microcirculation will be examined by Cytocam. The following microcirculatory
parameters will be investigated: total small vessel density, perfused small vessel density,
microvascular flow index, and heterogeneity index. The enzyme-linked immunosorbent assays
will be used to measure serum level of endocan, diamine oxidase, and neutrophil
gelatinase-associated lipocalin at preset time points. The primary goal of this study is to
compare the effect on microcirculation between dexmedetomidine and propofol in intensive care
unit patients after abdominal surgery.